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ABSTRACT
Purpose The aims of this study were two-fold: (i) to investigate the effect of exposure to antibiotic agents on the risk of acute liver injury
using a self-controlled case series and case-crossover study and (ii) to compare the results between the case-only studies.
Methods For the self-controlled case series study relative incidence ratios (IRR) were calculated by dividing the rate of acute liver injury
experienced during patients’ periods of exposure to antibiotics to patients’ rate of events during non-exposed time using conditional Poisson
regression. For the case-crossover analysis we calculated Odds Ratios (OR) using conditional logistic regression by comparing exposure dur-
ing 14- and 30-day risk windows with exposure during control moments.
Results Using the self-controlled case series approach, the IRR was highest during the ﬁrst 7 days after receipt of a prescription (10.01,
95% CI 6.59–15.18). Omitting post-exposure washout periods lowered the IRR to 7.2. The highest estimate in the case-crossover analysis
was found when two 30-day control periods 1 year prior to the 30-day ALI risk period were retained in the analysis: OR= 6.5 (95% CI, 3.95–
10.71). The lowest estimate was found when exposure in the 14-day risk period was compared to exposure in four consecutive 14-day con-
trol periods immediately prior to the risk period (OR= 3.05, 95% CI, 2.06–4.53).
Conclusion An increased relative risk of acute liver injury was consistently observed using both self-controlled case series and case-
crossover designs. Case-only designs can be used as a viable alternative study design to study the risk of acute liver injury, albeit with some
limitations. © 2015 The Authors Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.
key words—self-controlled case series; case-crossover; acute liver injury; antibiotic agents; CPRD; pharmacoepidemiology
Received 3 October 2014; Revised 6 July 2015; Accepted 7 July 2015
INTRODUCTION
Electronic health records offer great opportunities for
pharmacoepidemiological research into rare diseases
such as acute liver injury. One of the current key
challenges is how to correct for confounding factors
that are difﬁcult to measure using these electronic
health records, such as genetic susceptibility. Case-
only designs, in which cases act as their own
control, can provide some advantages over the more
traditional designs as they implicitly control for
confounders that do not vary over time.1–3 As acute
liver injury (ALI) is often idiosyncratic and the un-
derlying risk of patients who experience ALI may
differ from patients who never experience liver
injury, the self-controlled case series and the case-
crossover design were used to investigate the rela-
tionship between antibiotic agents and ALI.
The aims of this study were two-fold: (i) to
investigate the effect of exposure to antibiotic agents
on the risk of acute liver injury using a self-controlled
case series and case-crossover study and (ii) to
compare the results between the case-only studies;
and explore potential biases likely to result from the
study designs. The latter objective addresses one of
the main purposes of the IMI-PROTECT project, in
which this study was embedded.4
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METHODS
Source- and study population
The database and the source population were identical
to those described in a previous paper by our group.5
Brieﬂy, follow-up started at the earliest of 12months
after the start of Clinical Practice Research Datalink
(CPRD) registration from 2004 onwards and ended
at the earliest of the end of the CPRD record and De-
cember 2009. All patients from the source population
who received a prescription for an antibiotic agent
and who were diagnosed with acute liver injury during
their follow-up time were included in the self-
controlled case series and case-crossover studies. The
start date for all cases was 1 January 2004 or after
1year of research quality follow-up (whichever came
later). In the case-crossover analysis the follow-up pe-
riod ended at the date of acute liver injury.
Patients diagnosed with alcohol-related problems,
cancer, gallbladder disease, pancreatic disease, viral
hepatitis and other (chronic) liver diseases prior to
or on the date of their liver injury were excluded.
The algorithm that was used to deﬁne acute liver in-
jury has been described in detail by Ruigomez
et al.5 Brieﬂy, medical ﬁles were searched for speciﬁc
codes related to liver disease or symptoms, followed
by an assessment of laboratory test results. In addi-
tion, cases had to be referred to a specialist or hospital
related to liver disease within 2weeks of a recorded
diagnosis of liver injury.
Exposure was deﬁned as a recorded prescription for
an antibiotic agent listed in chapter 5 of the British
National Formulary (BNF). Prescriptions for topical
antibiotics were excluded. Duration of exposure was
calculated by dividing the total quantity of prescribed
antibiotics by the numeric daily dosage prescribed.
The median duration of exposure to all antibiotic agents
was imputed when information on the total quantity or
the prescribed daily dosage was missing (2%). An
individual was assumed to be exposed between the
end of their current prescription and a repeat prescrip-
tion if less than 14days had passed.
Self-controlled case series design
The rate ratio of the self-controlled case series
(SCCS) method is based on within-person compari-
sons rather than between-person comparisons.6
Patients who received an antibiotic agent during
follow-up and experienced an acute liver injury dur-
ing the study period were included and contributed
both exposed and unexposed person time. Each indi-
vidual’s exposed observation time was divided into
risk windows as follows: (i) from 0 to 7days after
the start of the treatment, (ii) from 8 to 14days after
the start of the treatment and (iii) from 15 to 30days
after the start of treatment and (iv) the remaining
exposed time, followed by (v) a period of 30days to
account for a gradual shift from exposed to unex-
posed time (a ‘wash-out’ period). The remaining
person-time was used as a baseline comparison
period. The 30-day washout period was divided into
three 10-day periods after treatment (see Figure 1).
The 7-day risk windows were chosen to reﬂect the av-
erage duration of a single exposure period. Subgroup
analyses were performed for users of tetracyclines,
penicillins, cephalosporins, quinolones, macrolides
and sulphonamides (and other combinations).
The case-crossover design
The case-crossover design shares similarities with a
self-controlled case series and case–control study de-
sign. As in the self-controlled case series design, only
patients that experienced the outcome of interest were
considered, and each case acted as his or her own con-
trol. The cases, with exposed time before the onset of
acute liver injury, and index dates in the case-
Start of
observation
period
First antibiotic
prescription
Washout period of 30 days
End of
observation
period
Baseline period
Risk period during exposure, divided into 4 risk windows
Figure 1. Diagram self controlled case series method ‘antibiotics and ALI’
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crossover analysis were the same as in our previous
nested case–control design (see Descriptive results).7
The timing of risk periods in the case-crossover design
was dependent on the timing of the acute liver injury
(like in a case–control study). Exposure to antibiotics
was ascertained in ﬁve periods preceding the index
date. Exposure in the case period, that is immediately
prior to the acute liver injury, was compared to expo-
sure in the past. The case period was deﬁned as the
14days immediately before the index date and this pe-
riod was compared to four successive 14-day cross-
over, or control periods starting immediately prior to
the case period (see Figure 2). Again, subgroup analy-
ses were performed by type of antibiotics.
Secondary analyses
We conducted the following secondary analyses:
1. The risk and control periods that were used in the
main self-controlled case series and case-crossover
analyseswere changed tomake themmore compara-
blewitheachother.For the self-controlled case series
analysis, the risk windows were changed to: (i) cur-
rent use, (ii) a washout period of up to 90days after
the end of the last prescription and (iii) a washout pe-
riodofup to365daysafter theendof the last prescrip-
tion. We considered several risk periods for each
patient in the case-crossover study population. First,
the case-crossover case and cross-over/control pe-
riods were extended to 30days. Next, instead of four
control periods, we used twelve 30-day control pe-
riods. Last, we conducted a case-crossover analysis
with two rather than four control periods of 30days
each. We compared the impact of choosing two
control periods immediately prior to the risk period
versus two control periods a year before the risk pe-
riod (see Figure 2).
2. To investigate a potential exposure time trend in
the year before the event date, we conducted a con-
trol cross-over analysis in which we included one
control free of ALI for every case.
3. We conducted a SCCS analysis in which we re-
moved the wash-out periods to create more compa-
rable observation periods.
4. A pre-exposure period of 60days was created to in-
vestigate short-term event-dependent ﬂuctuations
of exposure risk using the self-controlled case se-
ries design.
5. There was a possibility that liver injury might in-
crease the short-term risk of death thereby leading
to bias of an unpredictable nature. To examine the
possibility of non-random censoring of the
follow-up time we used a recently developed ex-
tension of the self-controlled case series.8
Statistical analyses
For the self-controlled case series study relative inci-
dence ratios were calculated by comparing the rate of
acute liver injury experienced during risk periods with
the rate of events during baseline time. Incidence rate
ratios for the self-controlled case series were calcu-
lated using conditional Poisson regression.1 The inci-
dence rate ratio was adjusted for age in 1-year
agebands as age was considered a potentially impor-
tant time-varying confounder.
For the case-crossover analysis we calculated Odds
Ratios (OR) using conditional logistic regression by
Figure 2. Diagram case-crossover study ‘antibiotics and ALI’
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comparing exposure during risk windows (case person
periods) with exposure during control periods.3
RESULTS SELF-CONTROLLED CASE SERIES
STUDY
Descriptive results
We identiﬁed 275 deﬁnite cases of acute liver injury
for the self-controlled case series. Seventy-six cases
were prescribed a single course of antibiotic agents
during their follow-up. The median duration of
follow-up was 6years. A single exposure period
lasted, on average, 7days. The median age of patients
at the time of their liver injury was 60.3years, and
47% of all patients were male (see Table 1).
The same cases were included in the case crossover
analysis, but 40 cases were prescribed antibiotics only
after the date of acute liver injury. As the case-
crossover analysis relies on information from discor-
dant pairs, these cases were omitted as they did not
contribute any information to the analysis (not ex-
posed during the case period and not exposed during
the control period).
Results self-controlled case series study
The crude and age-adjusted rate ratios that were found
by using the self-controlled case series design showed
strong evidence of an increase in risk associated with
the use of antibiotic agents. The rate ratio was highest
during the ﬁrst 7days after receipt of a prescription
(Rate Ratio [RR] 10.01, 95% CI 6.59–15.18) and
remained increased the 7days thereafter (IRR 5.18,
95% CI 1.61–16.66), see Table 2. There was strong
evidence of an increased risk during the remaining ex-
posed period and during the 30days after the end of
the last prescription (IRR 1st 10days after use: 5.67,
95% CI 3.61–8.89).
When the self-controlled case series analysis was
stratiﬁed to allow for the estimation of relative risks
of acute liver injury by agents grouped in broad clas-
ses, there were not enough cases to estimate the risk
in users of tetracyclines and macrolides. Among the
other agents the highest risk was found in users of
cephalosporins (IRR 1st 7days after use: 19.78, 95%
CI 9.31–42.03), followed by sulphonamides (IRR
17.79, 95% CI 8.15–38.82), penicillins (IRR 8.06,
95% CI 4.68–13.90) and quinolones (IRR 4.47, 95%
CI 0.59–33.67—data not shown).
Results case-crossover study
The results of the case-crossover analysis in which
both risk and control windows were set at 14days
showed strong evidence of an increase in risk of acute
liver injury during the 14days before the index date as
compared to the control periods up to 70days prior to
the index date (OR 3.05, 95% CI 2.06–4.53, Table 3).
When exposure was stratiﬁed by antibiotic class, the
highest risk was found for quinolones (OR 6.92, 95%
CI 1.29–36.96) and cephalosporins (OR 6.8, 95% CI
2.53–18.24), followed by tetracyclines (OR 3.27,
95% CI 0.68–15.68), sulphonamides (OR 3.19, 95%
CI 1.42–7.17) and penicillins (OR 2.58, 95% CI
1.58–4.22—data not shown). Using the case-crossover
approach, the risk of deﬁnite ALI in users of
macrolides was non-signiﬁcant (OR 1.34, 95% CI
0.42–4.24).
Results secondary analyses
1. When the risk periods of the self-controlled case
series analysis were collapsed to allow for the mea-
surement of current use of antibiotics, followed by
‘washout periods’, the main results did not change:
The IRR of acute liver injury during current use
was 11.6 (95% CI 7.57–17.79); the risk up to
90days after the end of the last prescription was
4.02 (95% CI 2.92–5.55); and the risk from 90 to
365days after the end of the last prescription was
1.86 (95% CI 1.33–2.59).
When the risk and four control periods of the
case-crossover analysis were changed to 30days,
qualitatively similar results were found (OR
4.76, 95% CI 3.27–6.95). Slightly higher esti-
mates were found when exposure to antibiotics
Table 1. Demographic details of the self-controlled case series study population at the time of the recording of an incident acute liver injury
First exposure
Patient group
(n = 275)
Before
ALI
After
ALI
Median duration of
eligible follow-up in years
(95% CI)
Median age at ﬁrst
exposure in years
(95% CI)
Median duration of
exposure in days
(95% CI)
Median age at time of
ALI in years
(95% CI)
All antibiotics 229 46 6.0 (5.64–6.0) 59.11 (56.0–61.87) 7 (7–7) 60.33 (56.46–63.32)
Males 104 26 5.9 (5.46–6.0) 59.10 (55.93–64.5) 7 (7–7) 60.48 (57.7–64.4)
Females 125 20 6.0 (5.59–6.0) 59.11 (52.85–63.78) 7 (7–7) 59.99 (53.76–64.9)
r. brauer et al.
© 2015 The Authors Pharmacoepidemiology and Drug Safety
Published by John Wiley & Sons Ltd.
Pharmacoepidemiology and Drug Safety, (2015)
DOI: 10.1002/pds
in the 30-day risk period was compared with ex-
posure in 12 previous consecutive 30-day control
periods: OR 5.17, 95% CI 3.76–7.09. The highest
relative risk estimate was found when only two
control periods of 30days each 1year prior to
the risk period were retained in the analysis
(OR 6.5, 95% CI 3.95–10.71), see Table 3.
2. Using a control cross-over analysis, we found no
evidence of an exposure time trend (OR 0.94,
95% CI 0.54–1.63).
3. Omitting the washout periods from the follow-up
time lowered the point estimate of risk during the
1st 7 days of antibiotic use (IRR 7.2, 95% CI
4.78–10.84) and the 7days thereafter (IRR 3.54,
95% CI 1.10–11.38).
4. There was no evidence that patients were at an in-
creased risk of ALI during the 60days before any
new exposure period. The risk of acute liver in-
jury during the pre-exposure period was 1.07
(95% CI 0.52–2.20, n=8). The addition of a
pre-exposure period did not alter the results of
the main analysis.
5. The observation period of nine percent of all pa-
tients ended within 60days of being diagnosed
with acute liver injury. We found no evidence of
bias because of non-random censoring of the obser-
vation period (IRR 1st 7 days of antibiotic use:
9.41, 95% CI 6.23–14.23 and IRR 1st 10days after
use: 5.38, 95% CI 3.44–8.40).
DISCUSSION
The relationship between antibiotic agents and acute
liver injury was investigated using two different
case-only study designs. The results of the self-
controlled case series and case-crossover analyses
showed strong evidence of an increase in the risk
of liver injury during the use of antibiotics. This al-
ready established drug-outcome association was
mainly chosen to facilitate a comparison of two
different case-only designs. Using the self-controlled
case series approach, the rate ratio was highest
during the ﬁrst 7days after receipt of a prescription
(IRR 10.01, 95% CI 6.59–15.18). The relative risk
Table 2. Results self-controlled case series analysis: the risk of deﬁnite ALI in users of antibiotics
Patient population self controlled case series
Exposure Nr of cases Person years
Rate ratio, unadjusted for age
(95%CI)
Age-adjusted rate ratio
(95% CI)
Non use (baseline time) 182 1206.6 Ref Ref
Current (0–7 days) 28 22.1 9.95 (6.57–15.07) 10.01 (6.59–15.18)
Current (7–14 days) 3 5.3 5.2 (1.62–16.7) 5.18 (1.61–16.66)
Current (15–30 days) 3 5.5 6.04 (1.83–20.0) 6.01 (1.81–19.91)
Current (>30 days) 6 19.3 6.52 (2.14–19.83) 6.05 (1.94–18.86)
Post-exposure period (1–10 days after exposure) 23 32.0 5.66 (3.61–8.86) 5.67 (3.61–8.89)
Post-exposure period (10–20 days after exposure) 17 30.8 4.35 (2.61–7.25) 4.35 (2.61–7.25)
Post-exposure period (20–30 days after exposure) 13 28.2 3.59 (2.03–6.37) 3.59 (2.02–6.37)
Table 3. Results case-crossover analysis: the risk of deﬁnite ALI in users of antibiotics
Exposure classiﬁcation Risk periods Control comparison periods Odds ratio 95% conﬁdence interval
All antibiotic agents
Four control periodsPrimary analysis:
Unexposed (ref)—14 days 47 324 1 Ref
Exposed 67 132 3.05 2.06–4.53
Secondary analyses:
Unexposed (ref)—30 days 44 390 1 Ref
Exposed 84 119 4.82 3.30–6.05
11 control periods
Unexposed (ref)—30 days 92 1720 1 Ref
Exposed 88 338 5.17 3.76–7.09
Two control periods with two windows of a month in between:
Unexposed (ref)—30 days 26 173 1 Ref
Exposed 81 41 5.44 3.48–8.5
Two control windows 1 year before the risk period:
Unexposed (ref)—30 days 20 30 1 Ref
Exposed 75 154 6.5 3.95–10.71
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remained very high (IRR=4) during the period
lasting to 90days post-exposure and the risk was still
high (RR=1.86) during the remainder of the year
post-exposure. Relative risk estimates in the case-
crossover analysis were consistently lower. The
lowest estimate was found in the primary case-
crossover analysis when antibiotic exposure in the
14-day risk period was compared to exposure in four
consecutive 14-day control periods immediately prior
to the risk period (OR=3.05, 95% CI 2.06–4.53).
The highest estimate was found when two 30-day
control periods 1year prior to the 30-day ALI risk
period were retained in the analysis: OR 6.5 (95%
CI 3.95–10.71).
Comparison of case-only designs
In the primary analysis of the SCCS study a post-
exposure period of 30days was included to represent
a gradual shift from full exposure to an entirely unex-
posed state. The results of the secondary analyses
showed that omission of these post-exposure periods,
by adding them to the baseline comparison time,
somewhat narrowed the difference between the results
of the SCCS and the primary case-crossover analysis.
Omitting the washout periods lowered the IRR to
7.2, which was similar to the OR found using the
case-crossover approach with control periods that
were 11 to 13months removed from the date of acute
liver injury (OR=6.5). The relatively low risk estimate
that was found in the primary case-crossover analysis
(OR=3.05), compared to the risk estimates found in
the secondary analyses, conﬁrms the increased risk
of ALI during post-exposure periods. The relatively
low risk is reﬂective of the choice of a limited number
of small control periods immediately prior to the risk
period. When longer and more distant control periods
were included in the case-crossover analysis the odds
ratios increased, thereby reducing the difference in es-
timates between the case-only designs. There was
strong evidence of an increased risk of ALI during
the 30days after the last day of recorded antibiotic
use and even up until 365days after the end of expo-
sure. It is worth noting that if the post-exposure risk
of ALI is true, and by conservatively using the lower
conﬁdence interval of the SCCS analysis, the relative
risk of ALI is increased 33% up to 1year after antibi-
otic exposure. This would cause more than twice as
many acute liver injuries as a true IRR of 11.6 during
actual exposure.
We found one further study using the self-controlled
case series method to investigate potential associations
between antibacterial agents and acute liver injury.
Ferrajolo et al. investigated signals of potential drug
induced liver injury and found a high risk in adoles-
cents and children in periods of antibiotic use com-
pared to non-exposed periods (IRR ranging from 2.6
(95% CI 0.8–9.3) for use of cefaclor to 16.7 (95% CI
9.9–28.1) for phenoxymethylpenicillin).9
Strengths and limitations
The results of the case-only studies were compared
with the adjusted results of a previously conducted
case–control study and a cohort study.7 The risk
periods and study populations were not directly com-
parable between study designs as the case-only de-
signs were used to analyse a temporal change in risk
within persons rather than a difference in risk between
persons.10 Still, the relative risk estimates using the
case-only and traditional designs were similar in direc-
tion: The IRR found in the self-controlled case series
was within the CIs for the cohort analysis (IRR 7.31,
95% 4.91–10.89), and the results of the case-crossover
analysis using 30-day windows were within the CI of
the adjusted case–control study (OR 5.70, 95% CI
3.46–9.36). This suggests that between person-
confounding was adequately accounted for in the
case–control and cohort analyses. The case-crossover
and self-controlled case series analyses both provided
some advantages over the more traditional designs
(cohort- and case–control study). Because compari-
sons were made within persons rather than between
persons, non time-varying confounding variables did
not affect the results as these were implicitly con-
trolled for.
Case-only study designs are better placed to assess
the effect of accurately dated treatments that are tran-
sient in nature. As all users in the case-only designs
used antibiotics intermittently, with most cases
(n=120) having received two to four prescriptions
over a six-year period, antibiotics were an ideal drug
to perform a case-crossover and a self-controlled case
series design. A speciﬁc assumption of the case-
crossover design that needs to be met is that the
exposure distribution in successive time periods
should be exchangeable. We did not identify an expo-
sure time trend nor any evidence of seasonality of
exposure. Indeed, when we tabulated ﬁrst exposure
to antibiotics per month, the treatment was distributed
roughly equally over all months, with slightly more
users in April, May and December (11%) versus all
other months (7%). We were not able to detect patients
who were prescribed antibiotic agents outside primary
care and we were not able to conﬁrm when and
whether a patient actually took the drug.
r. brauer et al.
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A speciﬁc assumption of the self-controlled case se-
ries method is that an event should not affect exposure.
If cases had been less likely to receive antibiotic agents
for a short period after acute liver injury, then the time
included after the liver injury would have been skewed
towards non-exposed time thereby introducing bias.
This would tend to lead to an overestimate of the rela-
tive risk during the exposed period. The case-
crossover study would clearly not be affected by this
bias as follow-up time is censored at the time of the
event. When we accounted for a potential change in
prescribing patterns after a diagnosis of ALI by creat-
ing a pre-exposure period, the relative risk in the pre-
exposure period was close to 1.00, suggesting no
evidence of a short-term change in the probability of
antibiotic use after ALI.
We acknowledge that the results of both case-only
designs may have been confounded by a temporal
change in underlying health at the time of their re-
ceipt of an antibiotic prescription. A limitation of
our studies was the uncertainty with regard to the
timing of the outcome as well as the validity of the
outcome. The time of onset of acute liver injury
was the date that a case presented with symptoms.
A delay in the recording of hospital events in pri-
mary care records or a delay in patients presenting
symptoms to their general practitioner could have af-
fected the risk estimates. Indirect evidence for this
theory can be seen with the continued increased rel-
ative risk observed in the self-controlled case series
at least 90days after antibiotic discontinuation
(4.02, 95% CI 2.92–5.55). By contrast, in the case
crossover analysis, a delay in liver injury recording
would tend to reduce the proportion of case periods
containing an antibiotic exposure, whilst earlier con-
trol periods would be more likely to contain an anti-
biotic exposure. The result of this would be to bias
the odds ratio towards the null; in our analysis the
case-crossover analysis yielded the lowest estimate
of relative risk, suggesting the timing of event re-
cords may well have affected our results.
Whilst case-only designs may not entirely be suit-
able to study transient acute events for which an accu-
rate date of onset cannot be determined using clinical
records, we believe that cohort and case–control de-
signs would be prone to bias because of ﬁxed con-
founders, whilst still being affected by the inaccurate
timing of the event of interest.
CONCLUSION
An increased relative risk of acute liver injury was con-
sistently observed using both self-controlled case series
and case-crossover designs. Both designs eliminate
between-person confounding, but other biases may pos-
sibly have affected the results. Case-only designs can be
used as a viable alternative study design to study the
risk of acute liver injury, albeit with some limitations.
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KEY POINTS
• The results of the self-controlled case series and
case-crossover showed strong evidence of an in-
crease in the risk of acute liver injury during the
use of antibiotics and several months post-exposure.
• The age-adjusted risk ratio estimates found in the
self-controlled case series study during the ﬁrst
days during and after antibiotic use suggested a
stronger association than the results of the case-
crossover study: When longer and more distant
control periods were included in the case-
crossover analysis the difference in estimates be-
tween the case-only designs was reduced.
• The results suggest that both designs can be very
informative, but biases can arise when assump-
tions are not met. Comparability of the designs
depends on the choice, timing and duration of
risk and control periods.
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